133 related articles for article (PubMed ID: 32662933)
1. Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: A naturalistic study.
De Carlo V; Vismara M; Grancini B; Benatti B; Bosi MF; Colombo A; Viganò CA; Dell'Osso B
Hum Psychopharmacol; 2020 Sep; 35(5):e2750. PubMed ID: 32662933
[TBL] [Abstract][Full Text] [Related]
2. A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders.
Findling RL; Robb AS; DelBello MP; Huss M; McNamara NK; Sarkis EH; Scheffer RE; Poulsen LH; Chen G; Lemming OM; Auby P
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):47-54. PubMed ID: 29035574
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
4. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder.
Gonda X; Sharma SR; Tarazi FI
Expert Opin Drug Discov; 2019 Jan; 14(1):81-89. PubMed ID: 30457395
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Tolerability of Supratherapeutic Dosing of Vortioxetine in Patients With Treatment-Resistant Depression.
Cuomo A; Santucci A; Chioccioli M; Goracci A; Bolognesi S; Fagiolini A
Prim Care Companion CNS Disord; 2022 Jun; 24(3):. PubMed ID: 35687882
[No Abstract] [Full Text] [Related]
6. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
Christensen MC; Florea I; Lindsten A; Baldwin DS
J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
[TBL] [Abstract][Full Text] [Related]
7. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
Chokka P; Bougie J; Rampakakis E; Proulx J
CNS Spectr; 2019 Jun; 24(3):338-347. PubMed ID: 29792585
[TBL] [Abstract][Full Text] [Related]
8. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study.
De Berardis D; Fornaro M; Anastasia A; Vellante F; Olivieri L; Rapini G; Serroni N; Orsolini L; Valchera A; Carano A; Tomasetti C; Ventriglio A; Bustini M; Pompili M; Serafini G; Perna G; Iasevoli F; Martinotti G; Di Giannantonio M
Braz J Psychiatry; 2020; 42(3):317-321. PubMed ID: 32159712
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis.
Li Z; Liu S; Wu Q; Li J; Yang Q; Wang X; Peng P; Wang Q; Liu Y; Li M; Hao Y; Xu H; He L; Wang Y; Chen S; Liu T
Int J Neuropsychopharmacol; 2023 Jun; 26(6):373-384. PubMed ID: 37105713
[TBL] [Abstract][Full Text] [Related]
11. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial.
Jacobsen P; Zhong W; Nomikos G; Clayton A
J Sex Med; 2019 Oct; 16(10):1638-1649. PubMed ID: 31405765
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis.
Zheng J; Wang Z; Li E
Afr Health Sci; 2019 Mar; 19(1):1716-1726. PubMed ID: 31149002
[TBL] [Abstract][Full Text] [Related]
13. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial.
Cao B; Park C; Rosenblat JD; Chen Y; Iacobucci M; Subramaniapillai M; Mansur RB; Zuckerman H; Lee Y; McIntyre RS
J Psychopharmacol; 2019 Nov; 33(11):1388-1394. PubMed ID: 31530216
[TBL] [Abstract][Full Text] [Related]
14. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials.
Mahableshwarkar AR; Affinito J; Reines EH; Xu J; Nomikos G; Jacobsen PL
CNS Spectr; 2020 Jun; 25(3):352-362. PubMed ID: 31199210
[TBL] [Abstract][Full Text] [Related]
15. A naturalistic, 24-week, open-label, add-on study of vortioxetine in bipolar depression.
Siwek M; Chrobak AA; Sołtys Z; Dudek D; Krupa AJ; Rybakowski JK
Psychiatr Pol; 2022 Jun; 56(3):509-522. PubMed ID: 36342982
[TBL] [Abstract][Full Text] [Related]
16. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial.
Mills NT; Sampson E; Fourrier C; Baune BT
Int J Neuropsychopharmacol; 2021 Apr; 24(4):314-321. PubMed ID: 33269395
[TBL] [Abstract][Full Text] [Related]
17. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
Subramaniapillai M; Mansur RB; Zuckerman H; Park C; Lee Y; Iacobucci M; Cao B; Ho R; Lin K; Phan L; McIntyre RS
Compr Psychiatry; 2019 Oct; 94():152113. PubMed ID: 31404802
[TBL] [Abstract][Full Text] [Related]
18. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
[No Abstract] [Full Text] [Related]
19. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
Christensen MC; Munro V
Curr Med Res Opin; 2018 Apr; 34(4):593-600. PubMed ID: 29235884
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant.
Atsou K; Ereshefsky L; Brignone M; Danchenko N; Diamand F; Mucha L; Touya M; Becker R; François C
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):29-42. PubMed ID: 33307885
[No Abstract] [Full Text] [Related]
[Next] [New Search]
